What Evofem Biosciences does

Evofem Biosciences, Inc. (OTCQB: EVFM) is a commercial-stage biopharmaceutical company headquartered in San Diego, California, focused on women's sexual and reproductive health. Its core platform is a vaginal pH modulator technology that maintains vaginal pH in the 3.5-4.5 baseline range to reduce sperm motility; this underpins its FDA-approved product PHEXX, the first and only hormone-free, on-demand prescription contraceptive vaginal gel launched in September 2020. In July 2024 Evofem acquired Lupin's U.S. women's health specialty business including SOLOSEC (secnidazole 2g oral granules), an FDA-approved single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis, which was relaunched in November 2024. The company is also developing EVO200, an investigational vaginal pH modulator for recurrent bacterial vaginosis prevention that has received FDA QIDP designation, and a preclinical Multipurpose Prevention Technology candidate in collaboration with Orion Biotechnology combining PHEXX with a CCR5 antagonist for HIV prevention.

Revenue comes principally from prescription product sales of PHEXX and SOLOSEC dispensed through U.S. retail pharmacies, with broader payer access supported by ACA-mandated no-cost coverage of FDA-approved contraceptives. Commercialization relies on a field sales force targeting OB/GYNs, family planning clinics, and primary care physicians, supplemented by payer/PBM formulary work, branded consumer campaigns (including the Say Vagina initiative), and ex-U.S. licensing partnerships (Pharma 1 for the Middle East, Clovis Davis Pharmaceuticals for Sub-Saharan Africa). FY 2025 net sales reached a record $20.2 million with $3.4 million of operating income. The company has raised over $93 million across multiple public and registered direct offerings since 2021, but a proposed $100 million merger with Aditxt was rejected by shareholders in October 2025, leaving Evofem as an independent public company focused on regaining a national listing and securing growth capital.

Name

Evofem Biosciences

Legal name

Evofem Biosciences, Inc.

Website

https://evofem.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Evofem Biosciences is a San Diego-based commercial-stage biopharmaceutical company that markets FDA-approved PHEXX (hormone-free contraceptive vaginal gel) and SOLOSEC (single-dose oral antibiotic for bacterial vaginosis and trichomoniasis), serving women of reproductive age and adolescents in the U.S. with planned ex-U.S. expansion.

Ownership category

akta.pro rank

Product category

Women's Reproductive Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Feminine & Sexual Wellness OTC (Yeast Infection OTC, Lubricants, Condoms, Pregnancy Tests) (CRADAMAH)

Keywords

• Hormone-free contraception
• Vaginal pH modulator
• Women's reproductive health
• Bacterial vaginosis treatment
• Prescription pharmaceuticals

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. PHEXX Product Sales: Prescription sales of PHEXX vaginal gel (lactic acid, citric acid, potassium bitartrate) to patients via retail pharmacies. Revenue driven by prescriber demand, payer formulary coverage, and ACA-mandated no-cost contraceptive coverage.
2. SOLOSEC Product Sales: Prescription sales of SOLOSEC (secnidazole 2g oral granules) acquired from Lupin in July 2024 and relaunched in November 2024. Covers bacterial vaginosis and trichomoniasis treatment in women and adolescents.
3. Ex-U.S. Licensing Revenue: Royalties and upfront/milestone payments from ex-U.S. licensing agreements for PHEXX and SOLOSEC, including Pharma 1 for Middle East and Clovis Davis Pharmaceuticals for Sub-Saharan Africa.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Evofem Biosciences develops and commercializes FDA-approved prescription pharmaceutical products for women's sexual and reproductive health. Its lead product PHEXX is the first and only FDA-approved hormone-free, on-demand vaginal contraceptive gel (lactic acid, citric acid, potassium bitartrate), and SOLOSEC is a single-dose oral antibiotic (secnidazole 2g) for bacterial vaginosis and trichomoniasis. Both are dispensed by prescription through U.S. retail pharmacies, with international commercialization executed via licensing and distribution partners.

Product overview

Evofem Biosciences is a commercial-stage biopharmaceutical company commercializing women's sexual and reproductive health products. The company markets two FDA-approved products: PHEXX, a first-in-class hormone-free on-demand contraceptive vaginal gel launched in September 2020, and SOLOSEC, an FDA-approved single-dose oral antibiotic for bacterial vaginosis and trichomoniasis acquired in July 2024 and relaunched in November 2024. The company is also developing EVO200 for recurrent Bacterial Vaginosis prevention and an MPT product candidate for HIV prevention in partnership with Orion Biotechnology.

Differentiator

Problem solved

Functional benefit

Brands

• PHEXX: FDA-approved hormone-free contraceptive vaginal gel (lactic acid, citric acid and potassium bitartrate)
• SOLOSEC
• EVO200
• EVO100

Products and services

• PHEXX FDA-approved hormone-free, on-demand prescription contraceptive vaginal gel containing lactic acid, citric acid, and potassium bitartrate; first-in-class Vaginal pH Modulator that maintains baseline vaginal pH (3.5-4.5) to reduce sperm mobility. Applied 0-60 minutes before intercourse, with 86% typical-use and 93% perfect-use effectiveness. Indicated for women seeking non-hormonal pregnancy prevention, including those with contraindications to hormonal contraceptives.
• SOLOSEC FDA-approved single-dose oral antimicrobial (secnidazole 2g granules) for the treatment of bacterial vaginosis and trichomoniasis in adults and adolescents aged 12 and older. Acquired from Lupin and relaunched by Evofem in November 2024, replacing multi-day antibiotic regimens with a single oral dose.

Quantifiable outcome

• 86% effective at preventing pregnancy with typical use; 93% effective with perfect use
• +4 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core, minor and strategic.

• Clovis Davis PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 27 April 2026Evofem entered an exclusive distribution agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC (secnidazole) for bacterial vaginosis and trichomoniasis in Sub-Saharan Africa. Clovis Davis leads distribution, promotion, marketing, and sales. Initial women's health initiatives are planned in Ethiopia and Uganda. Bacterial vaginosis is estimated to affect 25% of women in Sub-Saharan Africa.
• Pearsanta (Aditxt Subsidiary)minorStrategic or Co-development Partner · 20 September 2024Pearsanta, a subsidiary of Aditxt, planned to collaborate with Evofem Biosciences for the targeted U.S. launch of an endometriosis diagnostic in mid-2025. This partnership was announced during the period of the proposed Aditxt-Evofem merger, which was ultimately not approved by shareholders.
• Pharma 1coreOEM/ Whitelabel/ Licensing Partner · 23 July 2024Evofem signed an exclusive license agreement with Pharma 1 to commercialize PHEXX in the Middle East, including the UAE and other GCC countries. The Emirates Drug Establishment issued favorable pricing certificates for PHEXX in 2025. Launch is planned for 2026 pending regulatory approval, with potential expansion into other Middle Eastern and North African markets.
• Orion BiotechnologystrategicStrategic or Co-development PartnerEvofem is collaborating with Orion Biotechnology to evaluate the compatibility and stability of Orion's novel CCR5 antagonist OB-002 in PHEXX, with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for HIV prevention in women. The partnership is in preclinical stages, with plans to seek government and philanthropic funding for subsequent clinical trials.

Scale indicators15 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Organon & Co. Women's health specialty pharmaceutical company spun off from Merck in 2021, with a portfolio spanning contraception, fertility, and reproductive health. Comparable as a broad women's health commercial platform, though at much greater scale than Evofem.
• Bayer AG (Women's Health): Global pharmaceutical major with a large women's health franchise including Mirena, Kyleena, Yaz, and Beyaz. Competes broadly with PHEXX in hormonal and long-acting reversible contraception, though at much larger scale.
• AbbVie: Global biopharmaceutical company with women's health products including Lo Loestrin and the Lupron franchise. Broad incumbent in women's reproductive health, primarily competing in hormonal contraception.
• Perrigo Company / HRA Pharma: Consumer and specialty healthcare company with HRA Pharma franchise in women's health, including emergency contraception (Ella). Comparable in serving women's reproductive health with prescription and consumer products.

Direct peers

• TherapeuticsMD: Specialty pharmaceutical company focused on women's reproductive health with branded prescription products. Directly comparable business model of marketing women's health prescriptions through OB/GYN channels.
• Agile Therapeutics: Specialty pharma focused on women's contraception, including the Twirla contraceptive patch. Direct competitor in the prescription contraception space targeting similar OB/GYN and primary care prescribers.
• Daré Bioscience: Clinical-stage biopharmaceutical company with a portfolio of women's health product candidates spanning contraception and vaginal health. Comparable as a women's reproductive health innovator pursuing differentiated, hormone-free and specialty approaches.
• Mithra Pharmaceuticals: Belgian specialty pharma company focused on women's health, with products in contraception (Estelle) and vaginal health. Comparable as a specialty women's health company pursuing differentiated hormonal and non-hormonal products.
• Mayne Pharma: Specialty pharmaceutical company with a women's health portfolio that acquired TherapeuticsMD's assets. Direct comparable in specialty women's health commercialization, with overlapping OB/GYN and reproductive health focus.

Others

• Lupin Pharmaceuticals: India-based global pharmaceutical company that divested SOLOSEC to Evofem in July 2024 as part of its U.S. women's health specialty business. Connected through the asset transfer and overlapping therapeutic focus in women's health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Evofem
• Facebookfacebook.com/evofem
• LinkedInlinkedin.com/company/evofem-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds17 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evofem Biosciences